

Entod Pharma unveils world's first dry eye therapy Cyclotears Eye Drops

03 May 2023 | News

The first dry eye therapy to use the self-emulsifying drug delivery system (SEDDS) technology

Mumbai-based Entod Pharmaceuticals has announced the launch of CYCLOTEARS eye drops in India and its various global markets for patients with Inflammatory Dry Eye Disease (DED), a commonly occurring condition. CYCLOTEARS eye drops would be the first dry eye therapy in the world that incorporates the company's indigenously developed proprietary self-emulsifying drug delivery system (SEDDS) technology.

Nikhil K Masurkar, CEO, Entod Pharmaceuticals said "This novel technology used in CYCLOTEARS eye drops has been developed by Indian scientists at our Department of Scientific and Industrial Research (DSIR) accredited research centre. We are also associated with leading eye research institutes across India in the development phase. This technology is also backed by strong Indian generated clinical evidence published in international journals."

The prevalence of DED in India is higher than the global prevalence and stands at almost 32%, of which 90% were affected with moderate/severe DED. Studies have also shown that over-exposure of screens such as television, smartphones, computers, tablets & laptops or "screen time" significantly correlates with the severity of DED. It is projected that the prevalence of DED is likely to increase to 45% in India's urban population by 2030.